IMPACT OF THE ELGACIN ON THE ULTRASTRUCTURE OF LEFT VENTRICULAR IN RATS WITH SPONTANEOUS ARTERIAL HYPERTENSION

  2. 2014
  3. IMPACT OF THE ELGACIN ON THE ULTRASTRUCTURE OF LEFT VENTRICULAR IN RATS WITH SPONTANEOUS ARTERIAL HYPERTENSION
Show/Download

Publication of the article:

«Bulletin of problems biology and medicine», 2014 Issue 1, 106,

Dovgan R.

Impact of the Elgacin on the Ultrastructure of Left Ventricular in Rats with Spontaneous Arterial Hypertension

About the author:

Dovgan R.

Heading:

MORPHOLOGY

Type of article:

Scentific article

Annotation:

This work is a piece of research “Experimental study of combined use of cardiotropic drugs”, № of state registration 0111U 009,417. Introduction. In the treatment of arterial hypertension with antihypertensive drugs, even with the reduction in blood pressure, a complete reconstruction of structural damage of the myocardium in experimental rats with arte- rial hypertension (AH) doesn’t occurs. Although the question of whether oxidative stress is the cause or conse- quence of hypertension is widely disscused, but no doubt, that it is inextricably linked to oxidative stress. In this context, the aim of the study was to investigate the influence of elgacin (ellagic acid) on ultrastructure of myocardium of the left ventricle of rats with AH, which will detail some of the mechanisms of action of this drug. Materials and methods. By electron microscopy and morphometric analysis three groups of animals were ex- amined (7 in each group): normotensive rats of WKY lines; ISIAH line’s rat genetically predefined with AH and rats with AH treated with Elgacin dissolved in 1 mg / kg every once a day. The animals were kept in a vivarium conditions of the National Bogomelts Medical University at a constant temperature, sufficient natural light. results and discussion. The measuring of the blood pressure showed no significant changes in blood pressure levels before the experiment and at the end in all groups of the studied animals. In WKY rats the average blood pres- sure was equal to 103 ± 1 mm. Hg., 104 ± 1 mm. Hg. rats with AH – 157 ± 1 mm. Hg. and 156 ± 1 mm. Hg. rats after application of the AH elgacin – 154 ± 2 mm. Hg. and 153 ± 2,0 mm. Hg. In rats with AH after applying Elgacin on the cardiac left ventricle vary in the ultrastructure. There are cells with well-preserved myofibrils, forming typical sarcomere. In some areas of cardiomyocyte sarcomere contains local lysis of myofibrils. Are marked as contracted myofibrils, although their prevalence is lower than in untreated rats with AH. conclusions. Elgacin without causing a reduction of blood pressure in rats with AH, improves the contractile ap- paratus of cardiomyocytes of the left ventricle. This is evident decrease in the severity and prevalence of contracted myofibrils, preventing their destruction. This drug does not affect the state of the sarcoplasmic tubular mesh. Normalization of cardiomyocyte contractility caused property elgacin block oxidant stress, primarily in the mi- tochondria. This leads to the restoration of outer and inner membranes, thereby enhancing the formation of ATP deficiency which causes dissociation processes of contraction and relaxation of myofibrils. Antioxidant capacity of elgocin influences on the channels of microcirculation in the left ventricular myocardium of rats with AH, where there is active tumor microvessels and activation processes of transendotelial transfer agents.

Tags:

rat, arterial hypertension, elgatsin, electron microscopy, myocardium

Bibliography:

 

  • Довгань Р. С. Порівняльна морфометрична оцінка ефективності впливу біпрололу та його комбінації з препаратами метаболічного плану на кардіоміоцитищурів зі спонтанною артеріальною гіпертензією / Р. С. Довгань, Л. О. Стеченко, Т. П. Куфтирева [та ін.] // Вісн. морфології. – 2009. – Т. 15, № 1. – С. 1–4.
  • Довгань Р. С. Порівняльний аналіз змін вмісту жирних кислот в органах та крові щурів зі спонтанною артеріальною гіпертензією / Р. С. Довгань // Вісник проблем біології та медицини. – 2013. – Т. 2, № 2. – С. 97–101.
  • Загородний М. І. Вплив карведилолу на ультраструктуру міокарда щурів зі спонтанною артеріальною гіпертензією / М. І. Загородний, Т. П. Куфтирева, Л. О. Стеченко [та ін.] // Український кардіологічний журнал. – 2008 – № 6. – C. 79–83.
  • Загородний М. І. Вплив ліприлу на ультраструктуру міокарда щурів зі спонтанною артеріальною гіпертензією / М. І.Загородний, Л. О. Стеченко, Т. П. Куфтирєва [та ін.] // Лікарська справа. Врачебное дело. – 2008. – № 5−6. – С. 82–87.
  • Пузиренко А. М. Вивчення антигіпертензивної дії амлодіпіну, бісопрололу, елгаціну та їх комбінації у щурів зі спонтан- ною артеріальною гіпертензією / А. М. Пузиренко, А. горчакова Н. О., І. С. Чекман // галицкий мед. ж. – 2011. – Vol. 1. – P. 76–78.
  • Хворот О. П. Эллаговая кислота, распространенность в растительном мире и аспекты биологического действия / О. П. Хворот, В. В. Малый, А. г. Сербин [и др.] // Провизор. – 1998. – № 22. – C. 17–19.
  • Aggarwal B. B. Suppression of the nuclear factor-kappa B activation pathway by spice-derived phytochemicals: reasoning for seasoning / B. B. Aggarwal, S. Shishodia // Ann. NY Acad. Sci. – 2004. – Vol. 1030. – P. 434 –441.
  • Armani C. Molecular markers of cardiovascular damage in hypertension / C. Armani, N. Botto, M. G. Andreassi // Curr. Pharm.Des. – 2013. – Vol. 19. № 13. – P. 2341–2350.
  • Ceriello A. Possible role of oxidative stress in the pathogenesis of hypertension / А. Ceriello // Diabetes Care. – 2008. – Vol.31, № 2. – P. 181–184
  • Chan D. C. Mitocondrial Fusion and Fission in Mammals / D. C. Chan // Ann. Rev. Cell Dev. Biol. – 2006. – Vol. 22. – P. 79–99.
  • Chularojmontri L. Phyllanthus emblica L. Enhances Human Umbilical Vein Endothelial Wound Healing and Sprouting / L. Chu- larojmontri, M. Suwatronnakorn, S. K. Wattanapitayakul // Evid. Based Complement Alternat. Med. – 2013. – P. 720–728.
  • Grossman E. Does increased oxidative stress cause hypertension? / E. Grossman // Diabetes Care. – 2008. – Vol. 31, № 2. – P. 185–189.
  • Heber D. Multitargeted therapy of cancer by ellagitannins / D. Heber // Cancer Lett. – 2008. – Vol. 269, № 2. – P. 262–268.
  • Ito H. Metabolites of the ellagitannin geraniin and their antioxidant activities / H. Ito // Planta Med. – 2011. – Vol. 77, № 11. – P. 1110–1115.
  • Kannan M. M. Ellagic acid protects mitochondria from b-adrenergic agonist induced myocardial damage in rats; evidencefrom in vivo, in vitro and ultrastructural study / M. M. Kannan // Food Research International. – 2012. – Vol. 45, № 1. – P. 1–8.
  • Kannan M. M. Protective efficacy of ellagic acid on glycoproteins, hematological parameters, biochemical changes, and elec- trolytes in myocardial infarcted rats / M. M. Kannan, S. D. Quine, T. Sangeetha // J. Biochem. Mol Toxicol. – 2012. – Vol. 26,№ 7. – P. 270 –275.
  • Kannan M. Pharmacodynamics of ellagic acid on cardiac troponin-T, lyosomal enzymes and membrane bound ATPases: mechanistic clues from biochemical, cytokine and in vitro studies / M. Kannan, S. D. Quine // Chem. Biol. Interact. – 2011. – Vol. 193, № 2. – P. 154–161.
  • Klima Ł. The oxidative stress in pathogenesis of arterial hypertension – role of methylated arginines / Ł. Klima, K. Stolarz Skrzypek, R. Olszanecki [et al.] // Kardiol. Pol. – 2011. – Vol. 69, № 3. – P. 94–99.
  • Lindhout D. A. Structure and dynamics of the C-domain of human cardiac troponin C in complex with the inhibitory region of human cardiac troponin I / D. A. Lindhout, B. D. Sykes // J. Biol. Chem. – 2003. – Vol. 278, № 29. – P. 27024–2734.
  • Muсoz-Muсoz J. L. Ellagic acid: characterization as substrate of polyphenol oxidase / J. L. Muсoz-Muсoz, F. Garcia-Molina,M. Garcia-Molina [et al.] // IUBMB Life. – 2009. – Vol. 61, № 2. – P. 171–177.
  • Nambiar D. Effects of phytochemicals on ionization radiation-mediated carcinogenesis and cancer therapy / D. Nambiar, P. Rajamani, R. P. Singh // Mutat. Res. – 2011. – Vol. 728, № 3. – P. 139–157.
  • Pal C. Gallic acid prevents nonsteroidal anti-inflammatory drug-induced gastropathy in rat by blocking oxidative stress and apoptosis / C. Pal, S. Bindu, S. Dey [et al.] // Alam. Free Radic. Biol. Med. – 2010. – Vol. 49, № 2. – P. 258–267.
  • Parmacek M. S. Biology of the troponin complex in cardiac myocytes / M. S. Parmacek, R. J. Solaro // Prog. Cardiovasc. Dis.– 2004. – Vol. 47, № 3. – P. 159–176.
  • Parmer R. J. Plasma hydrogen peroxide production in human essential hypertension: role of heredity, gender, and ethnicity /R. J. Parmer, F. Lacy, M. T. Kailasam [et al.] // Hypertension. – 2000. – Vol. 36. – P 878–884.
  • Priscilla D. H. Cardioprotective effect of gallic acid on cardiac troponin-T, cardiac marker enzymes, lipid peroxidation products and antioxidants in experimentally induced myocardial infarction in Wistar rats / D. H. Priscilla, P. S. Prince // Chem. Biol. In- teract. – 2009. – Vol. 179, № 2-3. – P. 118–124.
  • Schulz E. Oxidative stress and endothelial dysfunction in hypertension / E. Schulz , T. Gori, T. Mьnzel // Hypertens. Res.– 2011. – Vol. 34, № 6. – P. 665–673.
  • Shaik A. H. Cardioprotective effect of HPLC standardized ethanolic extract of Terminalia pallida fruits against isoproterenol- induced myocardial infarction in albino rats / A. H. Shaik, S. N. Rasool, A. Vikram, K. Reddy [et al.] // J. Ethnopharmacol. – 2012. – Vol. 141, № 1. – P. 33–40.
  • Xie Y. Structures required of polyphenols for inhibiting advanced glycation end products formation / Y. Xie , X. Chen // Curr.Drug Metab. – 2013. – Vol. 14, № 4. – P. 414–431.

 

Publication of the article:

«Bulletin of problems biology and medicine» Issue 1 (106), 2014 year, 236-241 pages, index UDK 616. 127: 616. 124. 2: 57. 012. 4] – 085: 616. 12 – 008. 331. 1: 57. 085

2014 Issue 1, 106
17.03.2023
Was this article helpful?
18
3